Several studies suggest a role for xCT to counteract ROS in IDHwt GBM38–40 and xCT inhibitors such as sulfasalazine have been explored in clinical trials against GBM with little outcome.41,42 Yet sulfasalazine is highly toxic and affects multiple other pathways.43,44 The importance of xCT in IDHm gliomas remains to be determined. This evidence concerns the gene SLC7A11 and glioblastoma.